Mon Apr 20 03:02:43 SGT 2015  
SINGAPORE
GENITAL™
    Genital warts treatment, Singapore (SG)
HIV STD TESTING SINGAPORE™
HIV PEP: Stop HIV within 72 hours of sex HIV Test: 20 min result, 28 days after sex STD Testing: Full & comprehensive

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™

Summary

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™ @singaporegenital_com: Genital warts (condyloma, condylomata acuminata, venereal wart, anal wart, anogenital wart, "cauliflower" sex disease) screening/diagnosis, testing/check treatment/removal/cure, Singapore. Private and confidential service. Definitions, references, and latest news.

Description

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital warts treatment, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute HIV rapid test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute HIV rapid test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Zimbabwe: Cervical Cancer Common Among African Women
Sat, 18 Apr 2015 06:33:43 +0100 | AllAfrica News: Health and Medicine
[The Herald] Cervical cancer is caused by the sexually transmitted human papillomavirus (HPV), which is the most common viral infection of the reproductive tract. It affects younger age groups as a result of early sexual activity, multiple sexual partners, and exposure to other sexually transmitted infections such as HIV. (Source: AllAfrica News: Health and Medicine)

Detection and genotype of high-risk human papillomavirus in fine-needle aspirates of patients with metastatic squamous cell carcinoma is helpful in determining tumor origin.
Sat, 18 Apr 2015 02:06:17 +0100 | American Journal of Clinical Pathology
CONCLUSIONS: HR-HPV detection and genotyping can be performed on lymph node FNAs with metastatic squamous cell carcinoma using the Roche cobas 4800 system. The presence of HR-HPV and/or HPV 16 is a reliable indicator of the metastatic squamous cell carcinoma originating from the oropharynx.

Prevalence and genotype distribution of human papillomavirus infection in asymptomatic women in Liaoning province, China
Fri, 17 Apr 2015 22:25:15 +0100 | Journal of Medical Virology
Infection by human papillomavirus (HPV) is a necessary cause of cervical cancer. The purpose of this study was to investigate the prevalence and genotype distribution of HPV infection in Chinese women who were asymptomatic for cervical diseases. Cervical cytology samples were collected from 6479 asymptomatic Chinese women of Liaoning province, and tested for various HPV genotypes using a chip hybridization assay. HPV was found in 10.3% of all the asymptomatic women studied, with the prevalence of high risk HPV (HR HPV) and low risk HPV (LR HPV) being 9.5% and 1.1%, respectively. HPV genotypes 16, 52, and 58 were found the most frequently genotypes in the HR HPV positive women, and were present in 26.2%, 19.4% and 13.8%, respectively. A graph of HR HPV positive infection rates as a function...

Major clinical research advances in gynecologic cancer in 2014.
Fri, 17 Apr 2015 12:44:15 +0100 | Journal of Gynecologic Oncology
Authors: Suh DH, Lee KH, Kim K, Kang S, Kim JW

Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery.
Fri, 17 Apr 2015 12:44:15 +0100 | Journal of Gynecologic Oncology
CONCLUSION: Low initial HPV viral load may be a poor prognostic factor for cervical cancer patients who have undergone radical hysterectomy.

Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HLA-DQB1 and T-allele (rs16944) of IL-1β −511 is associated with development of cervical carcinoma
Fri, 17 Apr 2015 00:00:00 +0100 | Cancer Immunology, Immunotherapy
Abstract

Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme
Fri, 17 Apr 2015 00:00:00 +0100 | Sexually Transmitted Infections
Conclusions

Clinical round-up
Fri, 17 Apr 2015 00:00:00 +0100 | Sexually Transmitted Infections
HPV vaccination As we write, the Food and Drug Administration (USA) has approved the use of the 9-valent human papilloma virus (HPV) vaccine. Questions remain, however, about who to vaccinate. Should we be vaccinating boys/men, and how old is too old to be vaccinated? Skinner et al1 go some way to answering the second question with their interim analysis. The VIVIANE study is a multicentre double-blinded randomised controlled trial looking at the efficacy of the bivalent HPV 16/18 vaccine in women >25 years. (The PATRICIA study previously looked at this vaccine in women <25 years).2 In total, 15% of women included in the trial had prior exposure to HPV, and primary endpoints were persistent HPV 16/18 infection at 6 months or CIN1 or greater associated with these subtyp...

HPV positive oropharyngeal cancer and treatment deintensification: How pertinent is it?
Thu, 16 Apr 2015 00:00:00 +0100 | Journal of Cancer Research and Therapeutics
Sarbani Ghosh Laskar, Monali SwainJournal of Cancer Research and Therapeutics 2015 11(1):6-9In recent years there has been change in trends in the incidence of head and neck squamous cell carcinoma (HNSCC) with oropharyngeal carcinoma (OPC) showing an increased incidence, attributable specifically to infection by human papillomavirus (HPV). At the same time there is change in demographic characteristics and prognosis of this subset of HNSCC. Considering the better prognosis, researchers are trying to reduce the acute and long-term toxicities by alteration of various components of treatment protocols. Although treatment deintensification is an option for this group of patients, there is no standard protocol available and should be tried only in the protocol setting. (Source: Journal of Canc...

Tumor classification of human papilloma virus-related oropharyngeal squamous cell carcinomas is inconsistent
Thu, 16 Apr 2015 00:00:00 +0100 | Oral Oncology
Human papilloma virus (HPV) is established as the main cause of malignancy in the oropharynx [1,2]. Compared to HPV-negative carcinomas, HPV-positive oropharyngeal squamous cell carcinomas (OPSCCs) show different molecular, histopathologic, and clinical features, in addition to better treatment response and improved survival [2,3]. Tumor grading (i.e. tumor differentiation or classification) is important in tumor understanding. Conflicting opinions exist on how HPV-positive OPSCCs should be graded: The WHO classification from 2005 states that these tumors compose a distinct pathological entity with basaloid morphology, but does not clarify a grading scheme [4]. (Source: Oral Oncology)